JPRN-UMIN000018241
Completed
N/A
Feasibility study of neoadjuvant chemoradiotherapy using Intensity Modulated Radiation Therapy (IMRT) with Docetaxel, CDDP and 5-Fluorouracil (DCF) for cervical esophageal cancer. - OCD1501
Conditionscervical esophageal cancer
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- cervical esophageal cancer
- Sponsor
- Gunma University Hospital
- Enrollment
- 6
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) History of serious drug hypersensitivity 2\) Pregnant, lactating or women of child\-bearing potential. Men who want get partner pregnant 3\) Active infections 4 4\) Serious complications 5\) Serious heart disease 6\) Peptic ulcers 7\) Sensory neuropathy 8\) Diarrhea 9\) A case with abdominal dropsy and the hydrothorax to need a treatment 10\) Brain metastasis 11\) Other active malignancies (Nondisease period less than 5 years) 12\) Continuous steroid treatment 13\) Any other cases who are regarded as inadequate for study enrollment by the investigator 14\) Administration contraindication of 5\-FU, CDDP, Docetaxel
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Feasibility study of Neoadjuvant chemoradiotherapy for locally advanced esophageal carcinomaEsophageal CancerJPRN-UMIN000004223ational Cancer Center Hospital60
Completed
N/A
Feasibility trial of neoadjuvant chemoradiotherapy in patients with locally advanced gastric cancerGastric cancerJPRN-UMIN000004960Department of Gastroenterological Surgery, School of Medicine, Kagawa University16
Recruiting
N/A
A phase I/II study of neoadjuvant chemoradiotherapy for pancreatic cancer.JPRN-UMIN000042932The Jikei University school of medicine58
Recruiting
N/A
A feasibility study of neoadjuvant chemotherapy with mFOLFOX6 in patients with locally metastatic rectal cancerrectal cancerJPRN-UMIN000003428Toho University school of medicine20
Completed
N/A
A feasibility study of neoadjuvant chemotherapy with docetaxel+cisplatin+capecitabine (DCX) for HER2-negative gastric cancer with macroscopic type 4 and large type 3, or with multiple lymph node metastasisGastric cancerJPRN-UMIN000026783agoya University20